New drug shows promise for rare energy disorder
NCT ID NCT05972954
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fatigue. The goal was to see if OMT-28 is safe and could improve disease signs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OMT-28 (a drug taken once daily)
What this could lead to
If it works, this could point toward a treatment that reduces inflammation and improves energy levels in people with mitochondrial disease.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drug may not show clear benefits or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MITOCHONDRIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero Universitaria Pisana, P.O. Santa Chiara, U.O. Neurologia, Edificio 13, Via Roma 67
Pisa, 56126, Italy
-
Friedrich-Baur-Institut an der Neurologischen Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU Klinikum), Ziemssenstr. 1a
Munich, 80336, Germany
-
IRCCS Institute of Neurological Science of Bologna, University of Bologna, Department of Biomedical and Neuromotor Science (DIBINEM), Ospedale Bellaria Via Altura, 3
Bologna, 40139, Italy
-
IRCCS Istituto Neurologico Carlo Besta, SC Servizio Di Medicina Di Laboratorio - Genetica Medica E Neurogenetica, Via Celoria 11
Milan, 20133, Italy
-
Medizinisch Fakultät der Martin-Luther-Universität Halle-Wittenberg Universitätsklinik und Poliklinik für Neurologie Universitätsklinikum , Ernst-Grube-Str. 40
Halle, 06120, Germany
-
Radboud University Nijmegen Medical Centre
Nijmegen, Gelderland, 6500 HB, Netherlands
-
U.O.C. di Neurologia e Malattie Neuromuscolari
Messina, 98125, Italy
-
UOC di neurofisiopatologia
Roma, 8-00168, Italy
-
Universitätsklinikum Bonn, Sektion Neuromuskuläre Erkrankungen, Klinik und Poliklinik für Neurologie, Venusberg-Campus 1, Gebäude 80, NPP
Bonn, 53127, Germany